BIC/FTC/TAF Efficacy and Safety Similar to DTG-Based 3-Drug Regimens at Wk 144 in ART-Naive Patients Aged 50 Yrs or Older

March 8-11, 2020; Boston, Massachusetts
Long-term pooled analysis of Studies 1489 and 1490 demonstrated comparable efficacy and safety, including renal and bone outcomes, in older and younger patients initiating BIC/FTC/TAF vs DTG-based 3-drug regimens.
Format: Microsoft PowerPoint (.ppt)
File Size: 292 KB
Released: March 13, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Silvia Petretti on individualizing antiretroviral therapy according to patient factors from Clinical Care Options

person default Silvia Petretti Released: October 22, 2021

Clinical Care Options (CCO) expert analysis of new HIV data from IDWeek 2021, provided by expert HIV faculty

Eric S. Daar, MD Released: October 21, 2021

Slides from CCO: ART in Pregnancy: guideline recommendations and supporting data, pharmacokinetic considerations, and drug-drug interactions

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Jonah Musa, MBBS, MSCI, PhD Released: October 20, 2021

Expert selections of important HIV data from IDWeek 2021, including current and investigational ART, HIV PrEP, and metabolic outcomes of ART.

Eric S. Daar, MD Darcy Wooten, MD Released: October 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue